(R)-PFI-2 showed its activity in breast cancer cell MCF7 and mouse embryonic fibroblast in YAP-related studies (Barsyte-Lovejoy et al., 2014) and thus might be a potential therapeutic option for SETD7-mediated disease progression. Here, SETD7 is linked to breast cancer.